Xiaobin Wu Sells 1,459 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 1,459 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $159.79, for a total value of $233,133.61. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

BeiGene Trading Down 0.6 %

BeiGene stock opened at $145.58 on Friday. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $225.23. The firm’s 50 day moving average price is $156.67 and its 200-day moving average price is $160.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.08 and a quick ratio of 1.84. The stock has a market cap of $13.95 billion, a P/E ratio of -19.23 and a beta of 0.60.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, topping the consensus estimate of ($3.07) by $0.66. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The company had revenue of $751.70 million for the quarter, compared to analysts’ expectations of $670.09 million. During the same period in the previous year, the firm posted ($3.34) earnings per share. The firm’s revenue for the quarter was up 67.9% on a year-over-year basis. On average, equities analysts predict that BeiGene, Ltd. will post -8.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on BGNE. Bank of America cut their target price on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research report on Monday, April 8th. TD Cowen upped their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. lifted their target price on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a research report on Tuesday, March 19th. Finally, Sanford C. Bernstein decreased their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research note on Wednesday, March 27th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $251.93.

Institutional Trading of BeiGene

A number of hedge funds have recently bought and sold shares of BGNE. Capital International Investors boosted its holdings in shares of BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after buying an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of BeiGene by 6.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock worth $316,862,000 after purchasing an additional 117,905 shares in the last quarter. Capital International Inc. CA lifted its holdings in shares of BeiGene by 6.0% during the 1st quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock valued at $134,240,000 after purchasing an additional 48,615 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of BeiGene in the 4th quarter worth $39,632,000. Finally, Goldman Sachs Group Inc. raised its stake in BeiGene by 175.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after buying an additional 136,458 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.